Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Ad Comm thumbs down on Spectrum's apaziquone 14 – 0. I would think and hope they’ll shut down the ongoing P3 trial since I’m sure that the patent life for apaz will be non existent when the trial finishes up i.e. 2021-22. The link below indicates that a patient in a P3 study cost ~$42,000. At 1869 pts that’s over 78M so that’s about 15-20M per year for the next 3 yrs or so. Too bad, I really think pts could have used another drug in the tool chest but that’s reality.

http://www.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf